

Cellnovo appoints Sophie Baratte as Interim Chairman of the Board

Paris, France, April 11, 2016 – Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected all-in-one diabetes management system, today announced that Eric Beard has stepped down as Chairman of the Board for personal reasons, effective immediately. Sophie Baratte, CEO of Cellnovo, will assume the role of Interim Chairman whilst the Board searches for a permanent successor.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: *“Cellnovo and the Board are very grateful for Eric’s leadership and dedicated guidance, which have spanned the Company’s successful flotation in Paris and continued commercial development. We support his decision to step down for personal reasons and wish him well. A search for Eric’s successor has begun and we look forward to updating the market on progress.”*

•••

In the coming months, Cellnovo will participate in the following investor events:

- European 'Smallcap Event', April 11-12, Paris

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.



The First Connected All-in-one Diabetes Management System

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Emmanuel Huynh
+ 33 1 44 71 00 16

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Consilium Strategic Communications

Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Chris Welsh, Laura
Thornton
+44 20 3709 5700
cellnovo@consilium.com

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV

